HEIDELBERG PHARMA AG (HPHA.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:HPHA - DE000A11QVV0 - Common Stock
3.04 EUR
-0.02 (-0.65%)
Overall HPHA gets a fundamental rating of 2 out of 10. We evaluated HPHA against 86 industry peers in the Biotechnology industry. Both the profitability and financial health of HPHA have multiple concerns. HPHA is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
- In the past year HPHA has reported negative net income.
- In the past year HPHA has reported a negative cash flow from operations.
- HPHA had negative earnings in each of the past 5 years.
- In the past 5 years HPHA always reported negative operating cash flow.
1.2 Ratios
- HPHA's Return On Assets of -48.43% is on the low side compared to the rest of the industry. HPHA is outperformed by 62.79% of its industry peers.
- HPHA's Return On Equity of -248.59% is in line compared to the rest of the industry. HPHA outperforms 40.70% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -48.43% | ||
| ROE | -248.59% | ||
| ROIC | N/A |
ROA(3y)-26.81%
ROA(5y)-58.88%
ROE(3y)-44.53%
ROE(5y)-133.28%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Gross Margin of HPHA (84.66%) is better than 77.91% of its industry peers.
- In the last couple of years the Gross Margin of HPHA has grown nicely.
- The Profit Margin and Operating Margin are not available for HPHA so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 84.66% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y8.66%
2. Health
2.1 Basic Checks
- HPHA does not have a ROIC to compare to the WACC, probably because it is not profitable.
- HPHA has about the same amout of shares outstanding than it did 1 year ago.
- HPHA has more shares outstanding than it did 5 years ago.
- HPHA has a worse debt/assets ratio than last year.
2.2 Solvency
- HPHA has an Altman-Z score of -7.73. This is a bad value and indicates that HPHA is not financially healthy and even has some risk of bankruptcy.
- HPHA has a worse Altman-Z score (-7.73) than 74.42% of its industry peers.
- HPHA has a Debt/Equity ratio of 3.47. This is a high value indicating a heavy dependency on external financing.
- Looking at the Debt to Equity ratio, with a value of 3.47, HPHA is doing worse than 60.47% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 3.47 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -7.73 |
ROIC/WACCN/A
WACC7.15%
2.3 Liquidity
- A Current Ratio of 5.85 indicates that HPHA has no problem at all paying its short term obligations.
- The Current ratio of HPHA (5.85) is better than 84.88% of its industry peers.
- A Quick Ratio of 3.55 indicates that HPHA has no problem at all paying its short term obligations.
- Looking at the Quick ratio, with a value of 3.55, HPHA is in the better half of the industry, outperforming 70.93% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.85 | ||
| Quick Ratio | 3.55 |
3. Growth
3.1 Past
- HPHA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -35.76%.
- HPHA shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -64.15%.
- HPHA shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -1.29% yearly.
EPS 1Y (TTM)-35.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-43.71%
Revenue 1Y (TTM)-64.15%
Revenue growth 3Y57.6%
Revenue growth 5Y-1.29%
Sales Q2Q%-96.05%
3.2 Future
- The Earnings Per Share is expected to grow by 15.35% on average over the next years. This is quite good.
- HPHA is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.54% yearly.
EPS Next Y-44.19%
EPS Next 2Y15.13%
EPS Next 3Y15.35%
EPS Next 5YN/A
Revenue Next Year-15.81%
Revenue Next 2Y-3.55%
Revenue Next 3Y6.54%
Revenue Next 5YN/A
3.3 Evolution
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- HPHA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for HPHA. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A more expensive valuation may be justified as HPHA's earnings are expected to grow with 15.35% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.13%
EPS Next 3Y15.35%
5. Dividend
5.1 Amount
- HPHA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
FRA:HPHA (1/21/2026, 7:00:00 PM)
3.04
-0.02 (-0.65%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-09 2025-10-09
Earnings (Next)N/A N/A
Inst Owners2.03%
Inst Owner ChangeN/A
Ins Owners43.98%
Ins Owner ChangeN/A
Market Cap142.21M
Revenue(TTM)3.04M
Net Income(TTM)-26.18M
Analysts82.5
Price Target5.61 (84.54%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)22.22%
PT rev (3m)-59.56%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)12.06%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 46.82 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 13.5 | ||
| P/tB | 84 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.56
EYN/A
EPS(NY)-0.3
Fwd EYN/A
FCF(TTM)-0.68
FCFYN/A
OCF(TTM)-0.68
OCFYN/A
SpS0.06
BVpS0.23
TBVpS0.04
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -48.43% | ||
| ROE | -248.59% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 84.66% | ||
| FCFM | N/A |
ROA(3y)-26.81%
ROA(5y)-58.88%
ROE(3y)-44.53%
ROE(5y)-133.28%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y8.66%
F-Score1
Asset Turnover0.06
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 3.47 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 40.98% | ||
| Cap/Sales | 11.76% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 5.85 | ||
| Quick Ratio | 3.55 | ||
| Altman-Z | -7.73 |
F-Score1
WACC7.15%
ROIC/WACCN/A
Cap/Depr(3y)81.7%
Cap/Depr(5y)122.7%
Cap/Sales(3y)6.67%
Cap/Sales(5y)23.26%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-35.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-43.71%
EPS Next Y-44.19%
EPS Next 2Y15.13%
EPS Next 3Y15.35%
EPS Next 5YN/A
Revenue 1Y (TTM)-64.15%
Revenue growth 3Y57.6%
Revenue growth 5Y-1.29%
Sales Q2Q%-96.05%
Revenue Next Year-15.81%
Revenue Next 2Y-3.55%
Revenue Next 3Y6.54%
Revenue Next 5YN/A
EBIT growth 1Y-33.6%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-46.94%
EBIT Next 3Y16.64%
EBIT Next 5YN/A
FCF growth 1Y9.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y7.32%
OCF growth 3YN/A
OCF growth 5YN/A
HEIDELBERG PHARMA AG / HPHA.DE FAQ
Can you provide the ChartMill fundamental rating for HEIDELBERG PHARMA AG?
ChartMill assigns a fundamental rating of 2 / 10 to HPHA.DE.
What is the valuation status of HEIDELBERG PHARMA AG (HPHA.DE) stock?
ChartMill assigns a valuation rating of 0 / 10 to HEIDELBERG PHARMA AG (HPHA.DE). This can be considered as Overvalued.
What is the profitability of HPHA stock?
HEIDELBERG PHARMA AG (HPHA.DE) has a profitability rating of 1 / 10.
What is the financial health of HEIDELBERG PHARMA AG (HPHA.DE) stock?
The financial health rating of HEIDELBERG PHARMA AG (HPHA.DE) is 3 / 10.
Can you provide the expected EPS growth for HPHA stock?
The Earnings per Share (EPS) of HEIDELBERG PHARMA AG (HPHA.DE) is expected to decline by -44.19% in the next year.